Victor L. Villemagne mainly investigates Alzheimer's disease, Dementia, Pathology, Pittsburgh compound B and Internal medicine. The various areas that Victor L. Villemagne examines in his Alzheimer's disease study include Positron emission tomography, Neuroimaging, Neuroscience and Cognitive decline. His Dementia research is multidisciplinary, incorporating perspectives in Magnetic resonance imaging, Episodic memory, Clinical psychology, Apolipoprotein E and Cerebellar cortex.
His Pathology research includes themes of Neocortex and Posterior cingulate. Victor L. Villemagne focuses mostly in the field of Pittsburgh compound B, narrowing it down to matters related to Atrophy and, in some cases, Asymptomatic. His biological study spans a wide range of topics, including Endocrinology, Oncology and Cardiology.
Victor L. Villemagne mostly deals with Internal medicine, Disease, Alzheimer's disease, Pathology and Dementia. His Internal medicine study incorporates themes from Endocrinology, Cognition and Oncology. His Alzheimer's disease research focuses on Pittsburgh compound B in particular.
His Pathology study frequently links to related topics such as In vivo. Victor L. Villemagne combines subjects such as Neuroimaging and Cohort with his study of Dementia. His studies in Cognitive decline integrate themes in fields like Gerontology and Neuropsychology.
His main research concerns Internal medicine, Disease, Alzheimer's disease, Dementia and Cognitive decline. His Internal medicine study incorporates themes from Endocrinology, Cognition and Oncology. Disease is the subject of his research, which falls under Pathology.
His study explores the link between Pathology and topics such as White matter that cross with problems in Diffusion MRI. His research investigates the link between Alzheimer's disease and topics such as Neuroscience that cross with problems in Neurodegeneration. The Positron emission tomography study combines topics in areas such as Magnetic resonance imaging and Florbetaben.
Victor L. Villemagne mainly focuses on Alzheimer's disease, Internal medicine, Disease, Cognitive decline and Apolipoprotein E. The various areas that he examines in his Alzheimer's disease study include Amyloid beta, Dementia, Biomarker and Positron emission tomography, Neuroscience. The study incorporates disciplines such as Magnetic resonance imaging, Florbetaben, 18F-florbetaben and Pathology in addition to Positron emission tomography.
His Internal medicine study integrates concerns from other disciplines, such as Endocrinology, Cognition, Episodic memory and Oncology. His Disease research is multidisciplinary, relying on both Surgery, Dopaminergic, Cerebrospinal fluid and Gerontology. His work is dedicated to discovering how Cognitive decline, Cohort are connected with Ageing and other disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Victor L. Villemagne;Samantha Burnham;Pierrick Bourgeat;Belinda M. Brown.
Lancet Neurology (2013)
Imaging beta-amyloid burden in aging and dementia.
Christopher C Rowe;Steven Ng;Uwe Ackermann;Sylvia Gong.
Activation of memory circuits during cue-elicited cocaine craving
Steven Grant;Edythe D. London;David B. Newlin;Victor L. Villemagne.
Proceedings of the National Academy of Sciences of the United States of America (1996)
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Christopher C Rowe;Kathryn A Ellis;Kathryn A Ellis;Miroslava Rimajova;Pierrick Bourgeat.
Neurobiology of Aging (2010)
β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
Kerryn Elizabeth Pike;Gregory Raymond Savage;Victor L Villemagne;Steven Ng.
Longitudinal Assessment of Aβ and Cognition in Aging and Alzheimer Disease
Victor L Villemagne;Kerryn E Pike;Gaël Chételat;Kathryn A Ellis.
Annals of Neurology (2011)
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease
Kathryn A Ellis;Ashley I Bush;David Darby;Daniela De Fazio.
International Psychogeriatrics (2009)
Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
Christopher C Rowe;Uwe Ackerman;William Browne;Rachel S Mulligan.
Lancet Neurology (2008)
Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428
Una D. McCann;Dean F. Wong;Fuji Yokoi;Victor Villemagne.
The Journal of Neuroscience (1998)
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura;Naoki Kaneko;Victor L Villemagne;Takashi Kato.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: